COVID-19 (Coronavirus)Lung CancerWeb Exclusives
Web Exclusives – March 20, 2020
LUNGevity and 4 other lung cancer organizations have provided information on the new coronavirus for people with lung cancer and other patients with cancer. This update also provides reliable sources of information for patients.
COVID-19 (Coronavirus)From Your NavigatorNewsworthyWeb Exclusives
Web Exclusives – March 18, 2020
COVID-19, the respiratory infection caused by the new coronavirus, is making headlines around the world. Find out what you need to know about this global disease outbreak and how to protect yourself.
Today, more people, including patients diagnosed with chronic lymphocytic leukemia, are living longer with cancer thanks to advancements in cancer treatments. Improvements in the chance for long-term cancer remission are clearly important but living with cancer can also bring a new set of challenges.
People with cancer, including people who have been diagnosed with chronic lymphocytic leukemia, do not need to face it alone. Valuable online and local resources are available for patients with cancer and their loved ones.
For many patients with chronic lymphocytic leukemia (CLL), treatment is personalized. This means that oncologists tailor their medication choices based on the patient’s unique CLL characteristics and medical status.
Targeted therapies are effective in controlling chronic lymphocytic leukemia (CLL). New research is now looking into the impact that these agents can have on autoimmune conditions.
A new type of immunotherapy, allogeneic cord blood–derived CAR NK-cells, could be a future option for patients with chronic lymphocytic leukemia (CLL), based on results from an early-phase clinical trial showing high response rates among patients.
Breast CancerWeb Exclusives
Web Exclusives – March 1, 2020
Machines that use artificial intelligence—such as Siri and Alexa—have become part of our everyday lives. Could this technology help in the fight against breast cancer? See how human doctors stacked up against machines in one study.
“Real World” Assessment of Side Effects and Discontinuation Rates in Patients with Chronic Lymphocytic Leukemia Treated with Ibrutinib
Web Exclusives – February 12, 2020
Ibrutinib is an orally administered Bruton tyrosine kinase inhibitor used in the treatment of patients with CLL. Because ibrutinib has been prescribed in the United States for several years, researchers sought to learn how the rates of side effects in the “real world” compared with those reported in clinical trials.
Page 1 of 12
Results 1 - 10 of 119
Results 1 - 10 of 119